Immunodiagnostic Systems, a producer of manual and automated specialist diagnostic testing kits, has announced the immediate departure of its Chief Executive Officer, Ian Cookson.
The company said it is now looking for a candidate who has "substantial diagnostic and international industry experience" and hopes to announce a new CEO in the near future.
The firm underwent a successful restructuring programme during the last quarter of the financial year in an effort to reduce its cost base in non-market facing operational areas.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, the group halved its pre-tax profits despite revenues coming in £3.5m higher at £53.67m. Regionally, revenues rose 19% in the US, but declined 2.1% in Rest of World (non-Europe and US).
Profit before tax fell from £16.5m to £7.2m, pushed lower by operating expenses and charges relating non-recurring items, while basic earnings per share plunged from 46.1p to 16.7p, principally due to the non-recurring costs and the change in accounting estimates.
The dividend for the year was increased from 2.50p to 2.75p following a period of strong cash generation.
In a statement the company said: "Trading for the first three months of the current financial year is in line with management expectations and we have continued to place additional IDS-iSYS systems. More recently we have secured new accounts for both our automated IDS-iSYS test for 1,25 dihydroxy vitamin D and also for our new hypertension assays launched within the past few weeks.
"We are working hard to continue to build the company and increase shareholder value in what is a challenging business environment. Despite the much more competitive market, we have increased our vitamin D revenues while at the same time diversifying the product range to broaden the appeal of the IDS-iSYS system and reduce the influence of changes in the vitamin D market.
"Costs are being continuously monitored to ensure resources are targeted at the key drivers for the business which are development productivity and niche marketing and sales activities to target the customer base benefiting most from the group's products."
The share price fell 7.14% to 260p by 12:53.
NR
-
Saba Capital and Boaz Weinstein respond to investment trustsAs investment trust managers and industry experts accuse Saba of self-motivated opportunism, the hedge fund responds to specific "misleading claims" and sets out its stall
-
How to find top-quality companies with growing dividendsIan Mortimer, portfolio manager of Guinness Global Equity Income Fund, shares where he would put his money for sustainable and growing dividends
